Logo image of PETS

PETMED EXPRESS INC (PETS) Stock Fundamental Analysis

NASDAQ:PETS - Nasdaq - US7163821066 - Common Stock - Currency: USD

3.5  -0.02 (-0.57%)

After market: 3.61 +0.11 (+3.14%)

Fundamental Rating

4

Taking everything into account, PETS scores 4 out of 10 in our fundamental rating. PETS was compared to 121 industry peers in the Specialty Retail industry. While PETS has a great health rating, there are worries on its profitability. PETS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

PETS had positive earnings in the past year.
In the past year PETS had a positive cash flow from operations.
Of the past 5 years PETS 4 years were profitable.
Each year in the past 5 years PETS had a positive operating cash flow.
PETS Yearly Net Income VS EBIT VS OCF VS FCFPETS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

Looking at the Return On Assets, with a value of 0.25%, PETS is in line with its industry, outperforming 47.93% of the companies in the same industry.
PETS's Return On Equity of 0.37% is in line compared to the rest of the industry. PETS outperforms 52.89% of its industry peers.
PETS has a Return On Invested Capital (1.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROIC 1.24%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
PETS Yearly ROA, ROE, ROICPETS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

PETS has a Profit Margin (0.14%) which is in line with its industry peers.
With a Operating Margin value of 0.62%, PETS is not doing good in the industry: 61.98% of the companies in the same industry are doing better.
Looking at the Gross Margin, with a value of 27.68%, PETS is doing worse than 71.07% of the companies in the same industry.
PETS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
PETS Yearly Profit, Operating, Gross MarginsPETS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

7

2. Health

2.1 Basic Checks

PETS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PETS has been increased compared to 1 year ago.
The number of shares outstanding for PETS has been increased compared to 5 years ago.
There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PETS Yearly Shares OutstandingPETS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PETS Yearly Total Debt VS Total AssetsPETS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.56 indicates that PETS is not in any danger for bankruptcy at the moment.
The Altman-Z score of PETS (3.56) is better than 81.82% of its industry peers.
There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.56
ROIC/WACC0.14
WACC9.18%
PETS Yearly LT Debt VS Equity VS FCFPETS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PETS has a Current Ratio of 1.43. This is a normal value and indicates that PETS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PETS (1.43) is comparable to the rest of the industry.
PETS has a Quick Ratio of 1.18. This is a normal value and indicates that PETS is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.18, PETS belongs to the best of the industry, outperforming 80.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.18
PETS Yearly Current Assets VS Current LiabilitesPETS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 102.56% over the past year.
PETS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.82%.
Measured over the past years, PETS shows a decrease in Revenue. The Revenue has been decreasing by -0.17% on average per year.
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%

3.2 Future

Based on estimates for the next years, PETS will show a very strong growth in Earnings Per Share. The EPS will grow by 29.72% on average per year.
PETS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.74% yearly.
EPS Next Y153.62%
EPS Next 2Y34.31%
EPS Next 3Y29.72%
EPS Next 5YN/A
Revenue Next Year-17.16%
Revenue Next 2Y-9.97%
Revenue Next 3Y-7.74%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PETS Yearly Revenue VS EstimatesPETS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
PETS Yearly EPS VS EstimatesPETS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

2

4. Valuation

4.1 Price/Earnings Ratio

PETS is valuated quite expensively with a Price/Earnings ratio of 350.00.
Based on the Price/Earnings ratio, PETS is valued a bit more expensive than 61.16% of the companies in the same industry.
PETS is valuated expensively when we compare the Price/Earnings ratio to 28.79, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for PETS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 350
Fwd PE N/A
PETS Price Earnings VS Forward Price EarningsPETS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PETS is valued cheaply inside the industry as 94.21% of the companies are valued more expensively.
The rest of the industry has a similar Price/Free Cash Flow ratio as PETS.
Industry RankSector Rank
P/FCF 84.57
EV/EBITDA 2.7
PETS Per share dataPETS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as PETS's earnings are expected to grow with 29.72% in the coming years.
PEG (NY)2.28
PEG (5Y)N/A
EPS Next 2Y34.31%
EPS Next 3Y29.72%

0

5. Dividend

5.1 Amount

PETS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PETMED EXPRESS INC

NASDAQ:PETS (4/25/2025, 8:00:00 PM)

After market: 3.61 +0.11 (+3.14%)

3.5

-0.02 (-0.57%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners44.55%
Inst Owner Change0.06%
Ins Owners8.21%
Ins Owner Change13.34%
Market Cap72.31M
Analysts42.86
Price Target3.67 (4.86%)
Short Float %12.1%
Short Ratio8.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.59
Dividend Growth(5Y)-11.13%
DP54.34%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-96.08%
Min EPS beat(2)-488.23%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)-36.55%
Min EPS beat(4)-488.23%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)-169.93%
EPS beat(12)4
Avg EPS beat(12)-128.55%
EPS beat(16)4
Avg EPS beat(16)-101.84%
Revenue beat(2)0
Avg Revenue beat(2)-12.18%
Min Revenue beat(2)-12.84%
Max Revenue beat(2)-11.51%
Revenue beat(4)1
Avg Revenue beat(4)-8.81%
Min Revenue beat(4)-12.84%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-6.94%
Revenue beat(12)1
Avg Revenue beat(12)-6.81%
Revenue beat(16)1
Avg Revenue beat(16)-6.96%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-80%
EPS NY rev (1m)0%
EPS NY rev (3m)20.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.07%
Valuation
Industry RankSector Rank
PE 350
Fwd PE N/A
P/S 0.29
P/FCF 84.57
P/OCF 14.97
P/B 0.75
P/tB 1.33
EV/EBITDA 2.7
EPS(TTM)0.01
EY0.29%
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.04
FCFY1.18%
OCF(TTM)0.23
OCFY6.68%
SpS11.96
BVpS4.66
TBVpS2.64
PEG (NY)2.28
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROCE 1.57%
ROIC 1.24%
ROICexc 2.57%
ROICexgc 23.86%
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
FCFM 0.35%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
F-Score7
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 57.96%
Cap/Sales 1.61%
Interest Coverage 250
Cash Conversion 57.63%
Profit Quality 239.5%
Current Ratio 1.43
Quick Ratio 1.18
Altman-Z 3.56
F-Score7
WACC9.18%
ROIC/WACC0.14
Cap/Depr(3y)91.99%
Cap/Depr(5y)95.64%
Cap/Sales(3y)1.43%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y153.62%
EPS Next 2Y34.31%
EPS Next 3Y29.72%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%
Revenue Next Year-17.16%
Revenue Next 2Y-9.97%
Revenue Next 3Y-7.74%
Revenue Next 5YN/A
EBIT growth 1Y111.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.4%
EBIT Next 3Y51.6%
EBIT Next 5YN/A
FCF growth 1Y-96.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.97%
OCF growth 3Y-52.42%
OCF growth 5Y-37.46%